Heska Corporation (NASDAQ:HSKA) veterinary diagnostic specialist, is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.33 per share.
Looking ahead, the full year loss are expected at $ 1.88 per share on the revenues of $ 177.69 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 175.00 million ~ $ 185.00 million
Click Here For More Historical Outlooks Of Heska Corporation
Stock Performance
Shares of Heska Corporation traded up $ 7.58 or 6.51 percent on Wednesday, reaching $ 123.99 with volume of 111.70 thousand shares. Heska Corporation has traded high as $ 124.12 and has cracked $ 118.78 on the downward trend
The closing price of $ 123.99, representing a 132.82 % increase from the 52 week low of $ 50.00 and a 6.21 % decrease over the 52 week high of $ 124.12.
The company has a market capital of $ 1.17 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Heska Corporation will be hosting a conference call at 11:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.heska.com
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The companys Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops.
